17285-76-6

Usage

Chemical Properties

Gray flake crystal

InChI:InChI=1/C8H10N2O2/c1-2-12-8(11)6-3-7(9)5-10-4-6/h3-5H,2,9H2,1H3

Upstream product

• 24242-19-1 5-aminonicotinic acid 
• 64-17-5 ethanol 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 

Downstream Products

• 126947-73-7 ethyl 5-(adamant-1-oylamino)nicotinate 
• 101512-23-6 Ethyl 5-(3,4,5-trimethoxybenzoylamino)-nicotinate 
• 632625-80-0 5-{2-[5-chloro-2-(hydroxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid ethyl ester 
• 632626-37-0 5-{2-[5-bromo-2-(hydroxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid ethyl ester 
• 632625-74-2 5-{2-[2-(hydroxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid ethyl ester 
• 632622-86-7 5-{2-[5-bromo-2-(2,4-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid 
• 632622-84-5 5-{2-[5-bromo-2-(3,4-dichlorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid 
• 632622-85-6 5-{2-[5-bromo-2-(2-chloro-4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid 
• 632621-87-5 5-{2-[5-chloro-2-(2-chloro-4-fluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid 
• 632621-89-7 5-{2-[5-chloro-2-(2,4-difluorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid 
• 632621-88-6 5-{2-[5-chloro-2-(3,4-dichlorobenzyloxy)phenyl]-5-methyl-pyrrol-1-yl}-nicotinic acid 

Relevant academic research and scientific papers

PROTEASOME ACTIVITY ENHANCING COMPOUNDS

The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, the methods of synthesis of the compouds of interest, and to methods for the treatment of a condition associated with a dysfunction in proteostasis, such as cancer, inflammatory conditions, neurodegeneration, metabolic conditions, comprising administering an effective amount of a compound of the invention.

SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES

The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heterocyclic Aza Compounds

Heterocyclic aza compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also methods of using these compounds for the treatment and/or inhibition of pain and further diseases and/or disorders.

SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands

Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.

Nicotinic acid adenine dinucleotide phosphate analogues containing substituted nicotinic acid: Effect of modification on Ca2+ release

Analogues of nicotinic acid adenine dinucleotide phosphate (NAADP) with substitution at either the 4- or the 5-position position of the nicotinic acid moiety have been synthesized from NADP enzymatically using Aplysia californica ADP-ribosyl cyclase or mammalian NAD glycohydrolase. Substitution at the 4-position of the nicotinic acid resulted in the loss of agonist potency for release of Ca2+-ions from sea urchin egg homogenates and in potency for competition ligand binding assays using [32P]NAADP. In contrast, several 5-substituted NAADP derivatives showed high potency for binding and full agonist activity for Ca2+ release. 5-Azido-NAADP was shown to release calcium from sea urchin egg homogenates at low concentration and to compete with [32P]NAADP in a competition ligand binding assay with an IC50 of 18 nM, indicating that this compound might be a potential photoprobe useful for specific labeling and identification of the NAADP receptor.

PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES

Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.